# Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities
Canonical URL: https://biopharmsignal.com/news/HRMY/harmony-biosciences-reports-q1-financial-results-and-confirms-2026-net-revenue-guidance-of-over-1-billion-reinforces-2026-strategic-priorities
Ticker: HRMY
Company: Harmony Biosciences
Source: Harmony Biosciences
Published: 2026-05-07 11:30 EST
Original Source URL: https://ir.harmonybiosciences.com
## Summary

WAKIX® Net Revenue Grew 17% to $215.4 Million for First Quarter 2026; On Track for Full Year 2026 Net Revenues over $1 Billion Continue to Vigorously Protect WAKIX IP into 2030; Filed Suit Against AET Pharma/Sandoz Regarding Infringement of Amorphous Pitolisant Patent Lifecycle Management Advancing

## Article Body
WAKIX® Net Revenue Grew 17% to $215.4 Million for First Quarter 2026; On Track for Full Year 2026 Net Revenues over $1 Billion Continue to Vigorously Protect WAKIX IP into 2030; Filed Suit Against AET Pharma/Sandoz Regarding Infringement of Amorphous Pitolisant Patent Lifecycle Management Advancing
## Recent Company News
- 2026-05-07 11:30 EST — [Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities](https://biopharmsignal.com/news/HRMY/harmony-biosciences-reports-q1-financial-results-and-confirms-2026-net-revenue-guidance-of-over-1-billion-reinforces-2026-strategic-priorities) — Source: Harmony Biosciences
- 2026-04-23 12:05 EST — [Harmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026](https://biopharmsignal.com/news/HRMY/harmony-biosciences-to-report-first-quarter-2026-financial-results-on-may-7-2026) — Source: Harmony Biosciences
- 2026-04-16 12:05 EST — [Harmony Biosciences to Present Open-Label Extension Data From Phase 3 ARGUS Trial at the 2026 American Academy of Neurology Annual Meeting](https://biopharmsignal.com/news/HRMY/harmony-biosciences-to-present-open-label-extension-data-from-phase-3-argus-trial-at-the-2026-american-academy-of-neurology-annual-meeting) — Source: Harmony Biosciences
- 2026-04-14 12:05 EST — [Harmony Biosciences Appoints Glenn Reicin as Chief Financial Officer](https://biopharmsignal.com/news/HRMY/harmony-biosciences-appoints-glenn-reicin-as-chief-financial-officer) — Source: Harmony Biosciences
- 2026-04-02 12:05 EST — [Harmony Biosciences Strengthens Executive Team With New Appointment and Announces Additions to Its Board](https://biopharmsignal.com/news/HRMY/harmony-biosciences-strengthens-executive-team-with-new-appointment-and-announces-additions-to-its-board) — Source: Harmony Biosciences
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)